Drug Overview
Gilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 1 (HER1), HER2, and HER4. In cancerous cells where EGFR and HER2 receptors are overexpressed, activation of these receptors can trigger cell-signaling pathways that lead to uncontrolled tumor cell proliferation. Gilotrif works by blocking these receptors, preventing their activation and thereby inhibiting the unwanted signaling pathways. Gilotrif irreversibly binds to two key receptors involved in cell proliferation, in comparison to first-generation TKIs which only provide single reversible receptor blocking.
Gilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 1 (HER1), HER2, and HER4. In cancerous cells where EGFR and HER2 receptors are overexpressed, activation of these receptors can trigger cell-signaling pathways that lead to uncontrolled tumor cell proliferation. Gilotrif works by blocking these receptors, preventing their activation and thereby inhibiting the unwanted signaling pathways. Gilotrif irreversibly binds to two key receptors involved in cell proliferation, in comparison to first-generation TKIs which only provide single reversible receptor blocking.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
